Home LiteratureArticle Details
PMID: 15041875 Published · ppublish fre Clinical Trial Clinical Trial, Phase IV Comparative Study English Abstract Journal Article Randomized Controlled Trial

[Treatment of functional signs of acute maxillary rhinosinusitis in adults. Efficacy and tolerance of administration of oral prednisone for 3 days].

Traitement des signes fonctionnels des rhinosinusites maxillaires aiguës de l'adulte. Efficacité et tolérance de la prednisone administrée par voie orale pendant 3 jours.

Presse medicale (Paris, France : 1983) ·Vol. 33 ·No. 5 ·2004-03-13 ·Pages 303-9

Klossek JM, Desmonts-Gohler C, Deslandes B, Coriat F, Bordure P, Dubreuil C, Gehanno P, Gilain L, Jankowski R, Serrano E, Stoll D

Abstract

Acute maxillary rhinosinusitis (AMRS) is a pathology in which the pain is often severe and requires appropriate treatment. Although the use of antibiotics is widely documented, the interest of short cycles of corticosteroids in the treatment of the functional manifestations of AMRS is based on professional experience. The aim of this study was to assess the efficacy and tolerance to prednisone administered for 3 days in addition to antibiotherapy in patients presenting with an AMRS. This was a double blind, randomised study in parallel groups and controlled versus a placebo, involving patients aged over 18, presenting with an AMRS confirmed by X-ray and endoscopy, having developed less than 5 days and complaining of spontaneous pain assessed as >or=50 millimetres on a visual analog scale (VAS). Together with cefpodoxime, the patients received either prednisone (0.8 to 1.2 mg/kg) for 3 days or a placebo. The primary efficacy endpoint was the mean of the differences versus the baseline value of pain (MPID - mean pain intensity difference) assessed on the VAS from Day 1 to Day 3. The secondary endpoints assessed were the mean of the differences in intensity of nasal obstruction, assessed in the same way as the MPID, the time lapse before the orally expressed relief of the pain (PRID - pain reflief intensity difference) and the administration of paracetamol during the first 3 days. 289 patients (placebo 147, prednisone 142) were assessable for analysis in intent-to-treat (ITT). The global spontaneous pain on inclusion, measured by a VAS was of 73.0 +/- 14.1 mm. The assessments made during the first 3 days of treatment showed a statistically significant difference in favour of the prednisone group regarding MPID: - 4.82 mm (CI 95% -9.25; -0.40) (p=0.03), nasal obstruction - 5.0 mm (CI 95% -9.1; -0.8) (p=0.02) and consumption of paracetamol (p=0.03). There was no difference between the two groups after the end of the antibiotherapy. The tolerance measured throughout the study was comparable between the two groups. This study clearly showed the efficacy of a short course of oral prednisone (3 days), versus a placebo, in the treatment of the functional signs of acute maxillary rhinosinusitis with severe pain in adults in addition to an appropriate antibiotic treatment.

MeSH Terms
Acetaminophen/adverse effects,therapeutic use Administration, Oral Adult Analgesics, Non-Narcotic/adverse effects,therapeutic use Anti-Bacterial Agents/adverse effects,therapeutic use Anti-Inflammatory Agents/administration & dosage,adverse effects,therapeutic use Ceftizoxime/adverse effects,analogs & derivatives,therapeutic use Double-Blind Method Drug Administration Schedule Drug Therapy, Combination Female Gastrointestinal Diseases/chemically induced Humans Male Maxillary Sinusitis/complications,drug therapy Middle Aged Nasal Obstruction/drug therapy,etiology Pain/drug therapy,etiology Pain Measurement Prednisone/administration & dosage,adverse effects,therapeutic use Rhinitis/drug therapy Treatment Outcome
Chemicals
Analgesics, Non-Narcotic Anti-Bacterial Agents Anti-Inflammatory Agents Acetaminophen cefpodoxime Ceftizoxime Prednisone
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Klossek J-M
Service ORL, Hôpital Jean Bernard la Miléterie, Poitiers. [email protected]
Desmonts-Gohler C
Deslandes B
Coriat F
Bordure P
Dubreuil C
Gehanno P
Gilain L
Jankowski R
Serrano E
Stoll D
Article Info
Journal
Presse medicale (Paris, France : 1983)
Abbr.
Presse Med
ISSN
0755-4982
Published
2004-03-13
Pages
303-9
Language
fre
Region
France
NLM ID
8302490
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]